PolyPid (Nasdaq:PYPD) - Aandelenkoers, Nieuws & Analyse

PYPD Overzicht aandelen

PolyPid Ltd., een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt doelgerichte therapeutica voor lokale toediening en verlengde afgifte met behulp van zijn eigen polymeer-lipide inkapseling matrix (PLEX) technologie om onvervulde medische behoeften aan te pakken. Meer informatie

PYPD fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 1.7% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

PolyPid Ltd. Concurrenten

Pulmatrix

NasdaqCM:PULM

US$22.4m

Cocrystal Pharma

NasdaqCM:COCP

US$22.4m

Cadrenal Therapeutics

NasdaqCM:CVKD

US$26.7m

Growth Stalk Holdings

OTCPK:GSTK

US$25.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor PolyPid
Historische aandelenkoersen
Huidige aandelenkoers	US$3.55
52 Week Hoogtepunt	US$9.20
52 Week Laag	US$2.95
Bèta	1.32
11 maand verandering	6.78%
3 maanden verandering	1.00%
1 Jaar Verandering	-13.54%
33 jaar verandering	-98.30%
5 jaar verandering	n/a
Verandering sinds IPO	-99.38%

Recent nieuws en updates

Recent updates

PolyPid set to cut 20% jobs

Oct 20

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

Sep 28

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

Sep 02

PolyPid GAAP EPS of -$1.23 misses by $0.60

Aug 10

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

Aug 03

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Mar 09

PolyPid's oncoplex cancer program shows encouraging action in animal study

Dec 22

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

Dec 16

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

Nov 24

Rendement voor aandeelhouders

	PYPD	US Pharmaceuticals	US Markt
7D	2.4%	1.6%	2.2%
1Y	-13.5%	9.9%	31.6%

Rendement versus industrie: PYPD presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 9.9 % opleverde.

Rendement versus markt: PYPD presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is PYPD's price volatile compared to industry and market?
PYPD volatility
PYPD Average Weekly Movement	8.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: PYPD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van PYPD is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	61	Dikla Czaczkes Akselbrad	www.polypid.com

PolyPid Ltd., een biofarmaceutisch bedrijf in klinische fase, ontwikkelt doelgerichte therapeutica voor lokale toediening en verlengde afgifte, gebruik makend van zijn eigen polymeer-lipide inkapseling matrix (PLEX) technologie om onvervulde medische noden aan te pakken. De belangrijkste productkandidaat is D-PLEX100, dat zich in een cruciale Fase 3-studie bevindt voor de preventie van SSI's (surgical site infections) bij patiënten die abdominale colorectale chirurgie met grote incisies ondergaan. Het ontwikkelt ook OncoPLEX, voor de behandeling van intra-tumorale kanker.

PolyPid Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van PolyPid zich tot de beurswaarde?
PYPD fundamentele statistieken
Marktkapitalisatie	US$24.12m
Inkomsten(TTM)	-US$26.86m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.9x

Koers/Winstverhouding

Is PYPD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PYPD resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$26.86m
Inkomsten	-US$26.86m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.95
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	357.1%

Hoe presteerde PYPD op de lange termijn?

Bekijk historische prestaties en vergelijking

PYPD Overzicht aandelen

Risicoanalyse

PolyPid Ltd. Concurrenten

NasdaqCM:PULM

US$22.4m

NasdaqCM:COCP

US$22.4m

NasdaqCM:CVKD

US$26.7m

OTCPK:GSTK

US$25.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

PolyPid Ltd. has filed a Follow-on Equity Offering in the amount of $8.25 million.

PolyPid Ltd. has filed a Follow-on Equity Offering in the amount of $8.25 million.

PolyPid Ltd. to Report Q3, 2024 Results on Nov 13, 2024

PolyPid Ltd. to Report Q2, 2024 Results on Aug 14, 2024

PolyPid Ltd. Hosts Kol Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on Its Ongoing Shield II Phase 3 Trial

PolyPid Ltd., Annual General Meeting, Jul 02, 2024

Recent updates

PolyPid Ltd. has filed a Follow-on Equity Offering in the amount of $8.25 million.

PolyPid Ltd. has filed a Follow-on Equity Offering in the amount of $8.25 million.

PolyPid Ltd. to Report Q3, 2024 Results on Nov 13, 2024

PolyPid Ltd. to Report Q2, 2024 Results on Aug 14, 2024

PolyPid Ltd. Hosts Kol Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on Its Ongoing Shield II Phase 3 Trial

PolyPid Ltd., Annual General Meeting, Jul 02, 2024

PolyPid Ltd. Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. to Report Q1, 2024 Results on May 08, 2024

PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial

PolyPid Ltd. to Report Q4, 2023 Results on Feb 14, 2024

PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.

PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors

Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors

PolyPid Ltd. to Report Q3, 2023 Results on Nov 08, 2023

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PolyPid Announces Reverse Share Split to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement

PolyPid Ltd. Announces Successful Completion of Manufacturing Process Validation for D-PLEX100

PolyPid Ltd. to Report Q2, 2023 Results on Aug 09, 2023

Polypid Ltd. Announces New Publication Highlighting Potent Antibacterial Activity of D-Plex Against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

PolyPid Ltd. Announces Recruitment of First Patient in Revised Shield Ii Phase 3 Trial Evaluating D-Plex100 for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

PolyPid Ltd Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. Announces Board Changes

PolyPid Ltd. to Report Q4, 2022 Results on Feb 08, 2023

PolyPid Provides Positive Regulatory Update for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Polypid Ltd. Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-Hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

Price target decreased to US$3.38

PolyPid Ltd. to Report Q3, 2022 Results on Nov 09, 2022

PolyPid set to cut 20% jobs

Polypid Ltd. Announces Eligibility for European Medicines Agency Centralized Procedure for D-Plex100 for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX100 in the Prevention of Surgical Site Infections in Abdominal Surgery

Price target increased to US$24.33

PolyPid Ltd. Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

PolyPid GAAP EPS of -$1.23 misses by $0.60

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

PolyPid Ltd. to Report Q2, 2022 Results on Aug 10, 2022

Polypid Ltd Announces Completion of Enrollment in Phase 3 Shield I Trial of D-Plex for Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

PolyPid Ltd. Announces Executive Changes

PolyPid: Strong Pipeline, Close Catalysts

PolyPid Ltd. announced that it expects to receive $15 million in funding from Kreos Capital Management (UK) Limited

PolyPid Ltd., Annual General Meeting, May 03, 2022

Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

PolyPid Ltd. Announces 750Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 in Abdominal Surgery

PolyPid Ltd. Announces 750Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 in Abdominal Surgery

PolyPid Ltd. Announces CEO Changes

Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

PolyPid Ltd. Announces Positive FDA Type B Meeting Feedback for D-Plex Development Program

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid Ltd., Annual General Meeting, Apr 13, 2021

Polypid Ltd. Announces 100Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 for the Prevention of Post-Abdominal Surgery Incisional Infections

New 90-day high: US$12.75

PolyPid Ltd. to Report Q4, 2020 Results on Feb 10, 2021